PEPTONIC medical Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Erik Sundquist

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	3yrs
CEO ownership	0.03%
Management average tenure	3yrs
Board average tenure	1yrs

Recent management updates

Recent updates

CEO

Erik Sundquist (53 yo)

3yrs

Tenure

Mr. Erik Sundquist, M.Sc. (Eng), serves as Chief Executive Officer at PEPTONIC medical AB (publ) since April 2021. He has been Marketing Director at PEPTONIC medical AB (publ) since October 1, 2017. He has...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Erik Sundquist	Chief Executive Officer	3yrs	no data	0.025% SEK 23.1k
Albert Lindgren	Chief Financial Officer	less than a year	no data	no data
Dan Markusson	Chief Operating Officer	3yrs	no data	0.10% SEK 92.2k
Heli Kurjanen	CEO of Lune Group Oy	no data	no data	0.59% SEK 540.4k

3.0yrs

Average Tenure

Experienced Management: PMED's management team is considered experienced (3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Tarek Shoeb	Director	1.3yrs	no data	no data
Anders Blom	Chairman of the Board	less than a year	no data	no data
Kristina Ingvar	Director	less than a year	no data	no data
Mika Kurjanen	Board Member Lune Group Oy Ltd	no data	no data	no data
Anders Norling	Independent Director	1.9yrs	no data	no data
Daniel Rudeklint	Director	no data	no data	no data

1.0yrs

Average Tenure

54yo

Average Age

Experienced Board: PMED's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.

PEPTONIC medical Management

Management criteria checks 1/4

Key information

Recent management updates

PEPTONIC medical AB (publ) Announces Chief Financial Officer Changes

PEPTONIC medical AB (publ), Annual General Meeting, May 21, 2024

PEPTONIC medical AB (publ) Announces Resignation of Albert Lindgren as CFO

Peptonic Medical AB (Publ) Appoints Albert Lindgren as Chief Financial Officer, Effective from October 21, 2023

Less than half of directors are independent

High number of new and inexperienced directors

Recent updates

PEPTONIC medical AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

PEPTONIC medical AB (publ) to Report Q2, 2024 Results on Aug 13, 2024

Peptonic Medical AB Granted Patent in Australia: Vernivia Secures Exclusivity Until 2038

Peptonic Medical AB Grants Patent in Europe for Relief of Provoked Vulvodynia in Women, Product Ready for Launch

PEPTONIC medical AB (publ) Announces Chief Financial Officer Changes

PEPTONIC medical AB (publ), Annual General Meeting, May 21, 2024

PEPTONIC medical AB (publ) to Report Q1, 2024 Results on May 07, 2024

PEPTONIC medical AB (publ) Announces Resignation of Albert Lindgren as CFO

Peptonic Medical AB (Publ) Announces Patented Apoteket Offering in 293 Apoteket Stores

Third quarter 2023 earnings released

Second quarter 2023 earnings released

Peptonic Medical AB (Publ) Appoints Albert Lindgren as Chief Financial Officer, Effective from October 21, 2023

District Court Rejects the Claim for A Corporate Fine and Acquits All in Insider Case Against Peptonic Medical AB (Publ)

PEPTONIC medical AB (publ) (NGM:PMED) signed a letter of intent to acquire Pharmiva AB (publ) (OM : PHARM) for SEK 15.2 million.

Pharmiva AB (publ) (OM:PHARM) entered in the letter of intent to acquire PEPTONIC medical AB (publ) (NGM:PMED).

Peptonic Medical AB (Publ) Announces the Application to Patent Its Intimate Cleaner in US to Be Approved on June 20, 2023

Less than half of directors are independent

First quarter 2023 earnings released

Full year 2022 earnings released: kr0.15 loss per share (vs kr0.39 loss in FY 2021)

High number of new and inexperienced directors

PEPTONIC medical AB (publ) Ongoing Applications for the Intimate Wash and for the Treatment of Fungal Infection Has Received Positive Statements from the International Review

Peptonic Medical AB (Publ) Announces Vagivital® Al Self-Test for Amniotic Fluid Leakage Detection Is Now Commercially Available for Sale in Its Own Online Store

Peptonic Medical's Ongoing Application for Vestibulitis Patent Receives Positive Opinion from the International Review

Second quarter 2022 earnings released: kr0.037 loss per share (vs kr0.064 loss in 2Q 2021)

High number of new and inexperienced directors

First quarter 2022 earnings released

No independent directors

Hans von Celsing, Leni Ekendahl, Marianne Östlund and Anna Tenstam Declines Re-Election to the Board of Directors of PEPTONIC medical AB (publ)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

PEPTONIC medical AB (publ) to Report Q3, 2022 Results on Nov 10, 2022

Peptonic Medical Introduces the Vagivital Range of Products to the US Market

Third quarter 2021 earnings released

PEPTONIC Initiates Non-Exclusive Negotiations Regarding a Possible Acquisition of All Assets in CommonSense Ltd (Israel)

Second quarter 2021 earnings released: kr0.064 loss per share (vs kr0.051 loss in 2Q 2020)

Peptonic Medical Gets Approval to Start a Clinical Trial for the Treatment of Vaginal Fungal Infections with an Adapted Version of VagiVital AktivGel

Peptonic Medical AB (Publ) Announces Latest Clinical Study with Vagivita

Peptonic Medical (publ) to Launch New Innovative Intimate Care Range Under Lunette Brand, Bringing Special Nordic Ingredients Down There

First quarter 2021 earnings released

New 90-day low: kr1.55

PEPTONIC medical AB (publ), Annual General Meeting, Jun 09, 2021

New 90-day low: kr1.60

Chief Financial Officer recently sold kr84k worth of stock

New 90-day low: kr1.68

Third quarter 2020 earnings released: kr0.041 loss per share

Peptonic to Launch the Self-Test Under the VagiVital® Brand

New 90-day low: kr1.98

Peptonic Medical AB Files Patent Application for the Treatment of Fungal Infections and Bacterial Vaginosis

New 90-day high - kr2.38

Earnings released

New 90-day high - kr2.24

PEPTONIC medical AB (publ) (NGM:PMED) exercised the option to acquire remaining 26.67% stake in Lune Group Oy Ltd for €1.2 million.

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age